Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review

• Main Authors: Stratigoula Sakellariou, Dionysia N. Zouki, Dimitrios C. Ziogas, Despoina Pouloudi, Helen Gogas, Ioanna Delladetsima
• Format: Article
• Language: English
• Published: BMC 2021-05-01
• Series: BMC Gastroenterology
• Subjects: Immune checkpoint inhibitors-related colitis; Immune checkpoint inhibitors-related adverse events; Intracryptal granulomas; Granulomatous colitis; Ipilimumab-related granulomas
• Online Access: https://doi.org/10.1186/s12876-021-01812-7

Abstract Background Immune checkpoint inhibitors (ICPIs) have changed the way advanced malignancies are currently confronted, improving cancer patients’ outcomes but also generating distinct immune-related (ir) adverse events. ICPIs-induced colitis is a common complication showing different clinical and histological manifestations. In the literature review, 14 cases with ICPIs related colon granulomas have been reported in 5 studies with either limited or unavailable information regarding histology. Granulomatous reactions can be mistakenly perceived as disease recurrence or progression. Better understanding and identification of this infrequent histological display can help to avoid misdiagnosis and mismanagement. Case presentation A 63-year-old female patient with metastatic melanoma was admitted to the hospital with symptoms of nausea, persistent diarrhea and shivering fever under consecutive treatments with ICPIs, initially pembrolizumab and subsequently ipilimumab. Sigmoidoscopy was performed revealing mucosal edema, hyperemia and erosions of the rectum and sigmoid colon. Histological evaluation of sigmoid colon mucosa biopsies revealed an unusual colitis pattern characterized by multiple intracryptal granulomas attributed to ICPIs therapy. Steroids were administered and the patient recovered. ICPIs treatment was discontinued. The patient was subsequently treated with chemotherapy but follow up radiology showed disease progression. A re-challenge with another ICPI regimen was decided and the patient is currently under immunotherapy with stable disease regarding melanoma status and without any sign of colitis recurrence. Conclusions The present report provides detailed histological description of a distinctive ICPIs-induced granulomatous colitis and highlights the need for awareness of the distinct adverse events and reaction patterns in the context of immunotherapy.